In the latest session, Moderna Inc. (NASDAQ: MRNA) closed at 129.71 up 1.41% from its previous closing price of $127.90. In other words, the price has increased by $+1.81 from its previous closing price. On the day, 8527083 shares were traded. MRNA reached its highest trading level at $134.35 during the session, while it also had its lowest trading level at $125.79.
For a deeper understanding of Moderna Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.43. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
Deutsche Bank Upgraded its Sell to Hold on January 26, 2022, while the target price for the stock was maintained at $175.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 15 when Bancel Stephane sold 40,000 shares for $137.11 per share. The transaction valued at 5,484,458 led to the insider holds 5,411,946 shares of the business.
Bancel Stephane sold 10,000 shares of MRNA for $1,386,200 on Sep 15. The Chief Executive Officer now owns 6,714,880 shares after completing the transaction at $138.62 per share. On Sep 14, another insider, Bancel Stephane, who serves as the Chief Executive Officer of the company, sold 40,000 shares for $138.82 each. As a result, the insider received 5,552,944 and left with 5,411,946 shares of the company.
As of this moment, Moderna’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.95, and their Forward P/E ratio for the next fiscal year is 14.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.18 while its Price-to-Book (P/B) ratio in mrq is 2.86.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $458.50, while it has fallen to a 52-week low of $115.61. The 50-Day Moving Average of the stock is 154.96, while the 200-Day Moving Average is calculated to be 167.01.
For the past three months, MRNA has traded an average of 4.92M shares per day and 6.07M over the past ten days. A total of 396.00M shares are outstanding, with a floating share count of 353.83M. Insiders hold about 5.40% of the company’s shares, while institutions hold 64.10% stake in the company. Shares short for MRNA as of Jul 14, 2022 were 16.29M with a Short Ratio of 3.09, compared to 14.76M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.09% and a Short% of Float of 5.49%.
There are 13 different market analysts currently analyzing its stock. On average, analysts expect EPS of $4.55 for the current quarter, with a high estimate of $5.34 and a low estimate of $2.02, while EPS last year was $6.46. The consensus estimate for the next quarter is $7.14, with high estimates of $13.09 and low estimates of $4.53.
Analysts are recommending an EPS of between $31.59 and $22.95 for the fiscal current year, implying an average EPS of $27.78. EPS for the following year is $8.66, with 19 analysts recommending between $21.24 and $-4.4.
A total of 11 analysts believe the company’s revenue will be $4.07B this quarter.It ranges from a high estimate of $4.7B to a low estimate of $2.54B. As of the current estimate, Moderna Inc.’s year-ago sales were $4.35B, an estimated decrease of -6.60% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $5.98B, a decrease of -3.70% over than the figure of $-6.60% in the same quarter last year. There is a high estimate of $10.44B for the next quarter, whereas the lowest estimate is $4.87B.
A total of 19 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $25.86B, while the lowest revenue estimate was $20.31B, resulting in an average revenue estimate of $22.02B. In the same quarter a year ago, actual revenue was $18.47B, up 19.20% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $10.39B in the next fiscal year. The high estimate is $18.61B and the low estimate is $3.99B. The average revenue growth estimate for next year is down -52.80% from the average revenue estimate for this year.